Lista de obras - Vittorio Maglione - Dominio Público Uruguay

Assessment of Blood-brain Barrier Permeability by Intravenous Infusion of FITC-labeled Albumin in a Mouse Model of Neurodegenerative Disease.

artículo científico publicado en 2017

Cavernous angiomas of the nervous system in Italy: clinical and genetic study

article

Changes of peripheral TGF-β1 depend on monocytes-derived macrophages in Huntington disease

artículo científico publicado en 2013

DNA instability in replicating Huntington's disease lymphoblasts

artículo científico publicado en 2009

De novo Synthesis of Sphingolipids Is Defective in Experimental Models of Huntington's Disease

artículo científico publicado en 2017

Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease

artículo científico publicado en 2017

FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease.

artículo científico publicado en 2013

Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice

artículo científico publicado en 2012

Genotype-, aging-dependent abnormal caspase activity in Huntington disease blood cells.

artículo científico publicado en 2011

Genotype-dependent priming to self- and xeno-cannibalism in heterozygous and homozygous lymphoblasts from patients with Huntington's disease

artículo científico publicado en 2006

Glyco-sphingo biology: a novel perspective for potential new treatments in Huntington's disease

artículo científico publicado en 2017

Glycosphingolipid metabolic reprogramming drives neural differentiation

artículo científico publicado en 2017

Highly disabling cerebellar presentation in Huntington disease.

artículo científico publicado en 2003

Highly variable penetrance in subjects affected with cavernous cerebral angiomas (CCM) carrying novel CCM1 and CCM2 mutations.

artículo científico publicado en 2007

Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course

artículo científico publicado en 2003

Impaired Levels of Gangliosides in the Corpus Callosum of Huntington Disease Animal Models

artículo científico publicado en 2016

Impaired ganglioside metabolism in Huntington's disease and neuroprotective role of GM1.

artículo científico publicado en 2010

Impairment of blood-brain barrier is an early event in R6/2 mouse model of Huntington Disease

artículo científico publicado en 2017

Italian Huntington disease patients--data and tissue bank.

artículo científico publicado en 2003

MRI measures of corpus callosum iron and myelin in early Huntington's disease.

artículo científico publicado en 2013

Motor phenotype is not associated with vascular dysfunction in symptomatic Huntington's disease transgenic R6/2 (160 CAG) mice

artículo científico publicado en 2017

Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations

artículo científico publicado en 2003

New Therapeutic Drugs from Bioactive Natural Molecules: the Role of Gut Microbiota Metabolism in Neurodegenerative Diseases

artículo científico publicado en 2018

Nitric oxide dysregulation in platelets from patients with advanced Huntington disease.

artículo científico publicado en 2014

Onset and pre-onset studies to define the Huntington's disease natural history.

artículo científico publicado en 2001

Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model

artículo científico publicado en 2015

Reduced bioavailable manganese causes striatal urea cycle pathology in Huntington's disease mouse model

artículo científico publicado en 2017

Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation

artículo científico publicado en 2005

Terapeutic Potential of Microencapsulated Sertoli Cells in Huntington Disease

artículo científico publicado en 2016

The Corticospinal Tract in Huntington's Disease.

artículo científico publicado en 2014

The longevity-associated variant of BPIFB4 improves a CXCR4-mediated striatum-microglia crosstalk preventing disease progression in a mouse model of Huntington's disease

scientific article published on 18 July 2020

The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington's disease patients with predominant chorea.

artículo científico publicado en 2005

Tractography of the corpus callosum in Huntington's disease

artículo científico publicado en 2013

ZPLD1 gene is disrupted in a patient with balanced translocation that exhibits cerebral cavernous malformations.

artículo científico publicado en 2008

Lista de obras de Vittorio Maglione

Assessment of Blood-brain Barrier Permeability by Intravenous Infusion of FITC-labeled Albumin in a Mouse Model of Neurodegenerative Disease.

Cavernous angiomas of the nervous system in Italy: clinical and genetic study

Changes of peripheral TGF-β1 depend on monocytes-derived macrophages in Huntington disease

DNA instability in replicating Huntington's disease lymphoblasts

De novo Synthesis of Sphingolipids Is Defective in Experimental Models of Huntington's Disease

Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease

FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease.

Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice

Genotype-, aging-dependent abnormal caspase activity in Huntington disease blood cells.

Genotype-dependent priming to self- and xeno-cannibalism in heterozygous and homozygous lymphoblasts from patients with Huntington's disease

Glyco-sphingo biology: a novel perspective for potential new treatments in Huntington's disease

Glycosphingolipid metabolic reprogramming drives neural differentiation

Highly disabling cerebellar presentation in Huntington disease.

Highly variable penetrance in subjects affected with cavernous cerebral angiomas (CCM) carrying novel CCM1 and CCM2 mutations.

Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course

Impaired Levels of Gangliosides in the Corpus Callosum of Huntington Disease Animal Models

Impaired ganglioside metabolism in Huntington's disease and neuroprotective role of GM1.

Impairment of blood-brain barrier is an early event in R6/2 mouse model of Huntington Disease

Italian Huntington disease patients--data and tissue bank.

MRI measures of corpus callosum iron and myelin in early Huntington's disease.

Motor phenotype is not associated with vascular dysfunction in symptomatic Huntington's disease transgenic R6/2 (160 CAG) mice

Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations

New Therapeutic Drugs from Bioactive Natural Molecules: the Role of Gut Microbiota Metabolism in Neurodegenerative Diseases

Nitric oxide dysregulation in platelets from patients with advanced Huntington disease.

Onset and pre-onset studies to define the Huntington's disease natural history.

Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model

Reduced bioavailable manganese causes striatal urea cycle pathology in Huntington's disease mouse model

Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation

Terapeutic Potential of Microencapsulated Sertoli Cells in Huntington Disease

The Corticospinal Tract in Huntington's Disease.

The longevity-associated variant of BPIFB4 improves a CXCR4-mediated striatum-microglia crosstalk preventing disease progression in a mouse model of Huntington's disease

The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington's disease patients with predominant chorea.

Tractography of the corpus callosum in Huntington's disease

ZPLD1 gene is disrupted in a patient with balanced translocation that exhibits cerebral cavernous malformations.